Sofinnova’s ‘pan-European’ play, China innovation and Trump’s tariff threat — a BioCentury podcast

How Biovelocita became the largest life sciences accelerator in Europe, the latest at FDA and more

European venture firm Sofinnova Partners is expanding the reach of its Biovelocita accelerator beyond Italy to stretch across the greater continent. On the latest BioCentury This Week podcast, BioCentury’s editors discuss how Biovelocita became the largest life sciences accelerator in Europe, the new fund that is supporting it and some of its portfolio companies.

The editors also discuss the latest addition by Novo Nordisk A/S (CSE:NOVO B; NYSE:NVO) to its obesity pipeline via a deal in China, and how the partnership reflects the state of cross-border dealmaking more broadly.

Finally, Washington Editor Steve Usdin assesses President Donald Trump’s threat to impose 25% tariffs on pharmaceutical imports, which has alarmed biopharma companies and spurred talk of mitigation strategies. He also provides an update on how FDA’s staff is navigating the policies of the new administration.